Global Methicillin-Susceptible Staphylococcus Aureus Market Research Report 2023

Publication ID:

PB502231312

Publication Date:

February 15, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

Methicillin-susceptible staphylococcus aureus infections are caused by gram-positive bacterium, which leads to skin allergies, pneumonia and endocarditis.
Highlights
The global Methicillin-Susceptible Staphylococcus Aureus market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Methicillin-Susceptible Staphylococcus Aureus is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Methicillin-Susceptible Staphylococcus Aureus is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Methicillin-Susceptible Staphylococcus Aureus in Hospitals is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Methicillin-Susceptible Staphylococcus Aureus include Dainippon Sumitomo Pharma Co., Ltd, Immtech Pharmaceuticals, Inc., Lytix Biopharma AS, PharmaIN Corporation, Cubist Pharmaceuticals, Kenta Biotech AG, Arsanis Biosciences GmbH, Volcano Corporation and Abbott Laboratories, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Methicillin-Susceptible Staphylococcus Aureus, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Methicillin-Susceptible Staphylococcus Aureus.
The Methicillin-Susceptible Staphylococcus Aureus market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Methicillin-Susceptible Staphylococcus Aureus market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Methicillin-Susceptible Staphylococcus Aureus companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Dainippon Sumitomo Pharma Co., Ltd
Immtech Pharmaceuticals, Inc.
Lytix Biopharma AS
PharmaIN Corporation
Cubist Pharmaceuticals
Kenta Biotech AG
Arsanis Biosciences GmbH
Volcano Corporation
Abbott Laboratories
AngioScore Inc.
Segment by Type
Cephalosporins
Vancomycin
Linezolid
Others
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Methicillin-Susceptible Staphylococcus Aureus companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Methicillin-Susceptible Staphylococcus Aureus Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Cephalosporins
1.2.3 Vancomycin
1.2.4 Linezolid
1.2.5 Others
1.3 Market by Application
1.3.1 Global Methicillin-Susceptible Staphylococcus Aureus Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Methicillin-Susceptible Staphylococcus Aureus Market Perspective (2018-2029)
2.2 Methicillin-Susceptible Staphylococcus Aureus Growth Trends by Region
2.2.1 Global Methicillin-Susceptible Staphylococcus Aureus Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Methicillin-Susceptible Staphylococcus Aureus Historic Market Size by Region (2018-2023)
2.2.3 Methicillin-Susceptible Staphylococcus Aureus Forecasted Market Size by Region (2024-2029)
2.3 Methicillin-Susceptible Staphylococcus Aureus Market Dynamics
2.3.1 Methicillin-Susceptible Staphylococcus Aureus Industry Trends
2.3.2 Methicillin-Susceptible Staphylococcus Aureus Market Drivers
2.3.3 Methicillin-Susceptible Staphylococcus Aureus Market Challenges
2.3.4 Methicillin-Susceptible Staphylococcus Aureus Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Methicillin-Susceptible Staphylococcus Aureus Players by Revenue
3.1.1 Global Top Methicillin-Susceptible Staphylococcus Aureus Players by Revenue (2018-2023)
3.1.2 Global Methicillin-Susceptible Staphylococcus Aureus Revenue Market Share by Players (2018-2023)
3.2 Global Methicillin-Susceptible Staphylococcus Aureus Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Methicillin-Susceptible Staphylococcus Aureus Revenue
3.4 Global Methicillin-Susceptible Staphylococcus Aureus Market Concentration Ratio
3.4.1 Global Methicillin-Susceptible Staphylococcus Aureus Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Methicillin-Susceptible Staphylococcus Aureus Revenue in 2022
3.5 Methicillin-Susceptible Staphylococcus Aureus Key Players Head office and Area Served
3.6 Key Players Methicillin-Susceptible Staphylococcus Aureus Product Solution and Service
3.7 Date of Enter into Methicillin-Susceptible Staphylococcus Aureus Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Methicillin-Susceptible Staphylococcus Aureus Breakdown Data by Type
4.1 Global Methicillin-Susceptible Staphylococcus Aureus Historic Market Size by Type (2018-2023)
4.2 Global Methicillin-Susceptible Staphylococcus Aureus Forecasted Market Size by Type (2024-2029)
5 Methicillin-Susceptible Staphylococcus Aureus Breakdown Data by Application
5.1 Global Methicillin-Susceptible Staphylococcus Aureus Historic Market Size by Application (2018-2023)
5.2 Global Methicillin-Susceptible Staphylococcus Aureus Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Methicillin-Susceptible Staphylococcus Aureus Market Size (2018-2029)
6.2 North America Methicillin-Susceptible Staphylococcus Aureus Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Methicillin-Susceptible Staphylococcus Aureus Market Size by Country (2018-2023)
6.4 North America Methicillin-Susceptible Staphylococcus Aureus Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Methicillin-Susceptible Staphylococcus Aureus Market Size (2018-2029)
7.2 Europe Methicillin-Susceptible Staphylococcus Aureus Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Methicillin-Susceptible Staphylococcus Aureus Market Size by Country (2018-2023)
7.4 Europe Methicillin-Susceptible Staphylococcus Aureus Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Methicillin-Susceptible Staphylococcus Aureus Market Size (2018-2029)
8.2 Asia-Pacific Methicillin-Susceptible Staphylococcus Aureus Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Methicillin-Susceptible Staphylococcus Aureus Market Size by Region (2018-2023)
8.4 Asia-Pacific Methicillin-Susceptible Staphylococcus Aureus Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Methicillin-Susceptible Staphylococcus Aureus Market Size (2018-2029)
9.2 Latin America Methicillin-Susceptible Staphylococcus Aureus Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Methicillin-Susceptible Staphylococcus Aureus Market Size by Country (2018-2023)
9.4 Latin America Methicillin-Susceptible Staphylococcus Aureus Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Methicillin-Susceptible Staphylococcus Aureus Market Size (2018-2029)
10.2 Middle East & Africa Methicillin-Susceptible Staphylococcus Aureus Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Methicillin-Susceptible Staphylococcus Aureus Market Size by Country (2018-2023)
10.4 Middle East & Africa Methicillin-Susceptible Staphylococcus Aureus Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Dainippon Sumitomo Pharma Co., Ltd
11.1.1 Dainippon Sumitomo Pharma Co., Ltd Company Detail
11.1.2 Dainippon Sumitomo Pharma Co., Ltd Business Overview
11.1.3 Dainippon Sumitomo Pharma Co., Ltd Methicillin-Susceptible Staphylococcus Aureus Introduction
11.1.4 Dainippon Sumitomo Pharma Co., Ltd Revenue in Methicillin-Susceptible Staphylococcus Aureus Business (2018-2023)
11.1.5 Dainippon Sumitomo Pharma Co., Ltd Recent Development
11.2 Immtech Pharmaceuticals, Inc.
11.2.1 Immtech Pharmaceuticals, Inc. Company Detail
11.2.2 Immtech Pharmaceuticals, Inc. Business Overview
11.2.3 Immtech Pharmaceuticals, Inc. Methicillin-Susceptible Staphylococcus Aureus Introduction
11.2.4 Immtech Pharmaceuticals, Inc. Revenue in Methicillin-Susceptible Staphylococcus Aureus Business (2018-2023)
11.2.5 Immtech Pharmaceuticals, Inc. Recent Development
11.3 Lytix Biopharma AS
11.3.1 Lytix Biopharma AS Company Detail
11.3.2 Lytix Biopharma AS Business Overview
11.3.3 Lytix Biopharma AS Methicillin-Susceptible Staphylococcus Aureus Introduction
11.3.4 Lytix Biopharma AS Revenue in Methicillin-Susceptible Staphylococcus Aureus Business (2018-2023)
11.3.5 Lytix Biopharma AS Recent Development
11.4 PharmaIN Corporation
11.4.1 PharmaIN Corporation Company Detail
11.4.2 PharmaIN Corporation Business Overview
11.4.3 PharmaIN Corporation Methicillin-Susceptible Staphylococcus Aureus Introduction
11.4.4 PharmaIN Corporation Revenue in Methicillin-Susceptible Staphylococcus Aureus Business (2018-2023)
11.4.5 PharmaIN Corporation Recent Development
11.5 Cubist Pharmaceuticals
11.5.1 Cubist Pharmaceuticals Company Detail
11.5.2 Cubist Pharmaceuticals Business Overview
11.5.3 Cubist Pharmaceuticals Methicillin-Susceptible Staphylococcus Aureus Introduction
11.5.4 Cubist Pharmaceuticals Revenue in Methicillin-Susceptible Staphylococcus Aureus Business (2018-2023)
11.5.5 Cubist Pharmaceuticals Recent Development
11.6 Kenta Biotech AG
11.6.1 Kenta Biotech AG Company Detail
11.6.2 Kenta Biotech AG Business Overview
11.6.3 Kenta Biotech AG Methicillin-Susceptible Staphylococcus Aureus Introduction
11.6.4 Kenta Biotech AG Revenue in Methicillin-Susceptible Staphylococcus Aureus Business (2018-2023)
11.6.5 Kenta Biotech AG Recent Development
11.7 Arsanis Biosciences GmbH
11.7.1 Arsanis Biosciences GmbH Company Detail
11.7.2 Arsanis Biosciences GmbH Business Overview
11.7.3 Arsanis Biosciences GmbH Methicillin-Susceptible Staphylococcus Aureus Introduction
11.7.4 Arsanis Biosciences GmbH Revenue in Methicillin-Susceptible Staphylococcus Aureus Business (2018-2023)
11.7.5 Arsanis Biosciences GmbH Recent Development
11.8 Volcano Corporation
11.8.1 Volcano Corporation Company Detail
11.8.2 Volcano Corporation Business Overview
11.8.3 Volcano Corporation Methicillin-Susceptible Staphylococcus Aureus Introduction
11.8.4 Volcano Corporation Revenue in Methicillin-Susceptible Staphylococcus Aureus Business (2018-2023)
11.8.5 Volcano Corporation Recent Development
11.9 Abbott Laboratories
11.9.1 Abbott Laboratories Company Detail
11.9.2 Abbott Laboratories Business Overview
11.9.3 Abbott Laboratories Methicillin-Susceptible Staphylococcus Aureus Introduction
11.9.4 Abbott Laboratories Revenue in Methicillin-Susceptible Staphylococcus Aureus Business (2018-2023)
11.9.5 Abbott Laboratories Recent Development
11.10 AngioScore Inc.
11.10.1 AngioScore Inc. Company Detail
11.10.2 AngioScore Inc. Business Overview
11.10.3 AngioScore Inc. Methicillin-Susceptible Staphylococcus Aureus Introduction
11.10.4 AngioScore Inc. Revenue in Methicillin-Susceptible Staphylococcus Aureus Business (2018-2023)
11.10.5 AngioScore Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Dainippon Sumitomo Pharma Co., Ltd
Immtech Pharmaceuticals, Inc.
Lytix Biopharma AS
PharmaIN Corporation
Cubist Pharmaceuticals
Kenta Biotech AG
Arsanis Biosciences GmbH
Volcano Corporation
Abbott Laboratories
AngioScore Inc.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂